Pembrolizumab, PD-1 Blocking Immune Checkpoint Inhibitor, for the Management of Periocular Sebaceous Carcinoma
H Demirci, Mehriban Alizada, Satinder Pal Singh, Dogukan Gurcan Arslan et autres
PURPOSE: To evaluate the efficacy of pembrolizumab, a programmed death-protein 1 (PD-1) immune checkpoint inhibitor, in the management of advanced ocular sebaceous carcinoma with pagetoid conjunctival spread, as well as in recalcitrant, recurrent, and metastatic disease. METHODS: Five patients with ocular sebaceous …
us (code pays fourni par la source)